[go: up one dir, main page]

AR129268A1 - ANTIBODY THAT BINDS TO VEGF-A AND IL6 AND METHODS OF USE - Google Patents

ANTIBODY THAT BINDS TO VEGF-A AND IL6 AND METHODS OF USE

Info

Publication number
AR129268A1
AR129268A1 ARP230101134A ARP230101134A AR129268A1 AR 129268 A1 AR129268 A1 AR 129268A1 AR P230101134 A ARP230101134 A AR P230101134A AR P230101134 A ARP230101134 A AR P230101134A AR 129268 A1 AR129268 A1 AR 129268A1
Authority
AR
Argentina
Prior art keywords
amino acid
seq
acid sequence
cdr
antibody
Prior art date
Application number
ARP230101134A
Other languages
Spanish (es)
Inventor
Roland Beckmann
Joerg Benz
Davide Bertoldo
Faye Marie Drawnel
Derrick Feenstra
Sebastian Fenn
Stefan Frost
Marlon Hinner
Kristian Hobolt Jensen
Daniela Matscheko
Anastasia Meier
Oliver Ploettner
Janina Speck
Pamela Strassburger
Barbara Marie Weiser
- Widmer Gabriella Luise
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR129268A1 publication Critical patent/AR129268A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a anticuerpos anti-VEGF-A / anti-IL6, por ejemplo, en forma de un fragmento Fab biespecífico, y sus métodos de uso. Reivindicación 1: Un anticuerpo que se une a VEGF-A humano y a IL6 humana que comprende un dominio VH que comprende (a) CDR-H1 que comprende la secuencia de aminoácidos de SEQ ID Nº 18, (b) CDR-H2 que comprende la secuencia de aminoácidos de SEQ ID Nº 19 y (c) CDR-H3 que comprende la secuencia de aminoácidos de SEQ ID Nº 20, y un dominio VL que comprende (d) CDR-L1 que comprende la secuencia de aminoácidos de SEQ ID Nº 15, (e) CDR-L2 que comprende la secuencia de aminoácidos de SEQ ID Nº 16 y (f) CDR-L3 que comprende la secuencia de aminoácidos de SEQ ID Nº 17, que comprende un dominio variable de la cadena pesada que comprende una secuencia de aminoácidos de SEQ ID Nº 22 con hasta 5 sustituciones de aminoácidos; y un dominio variable de la cadena liviana que comprende una secuencia de aminoácidos de SEQ ID Nº 21 con hasta 5 sustituciones de aminoácidos. Reivindicación 9: Un ácido nucleico aislado que codifica el anticuerpo de acuerdo con cualquiera de las reivindicaciones 1 a 8. Reivindicación 12: El método de acuerdo con la reivindicación 11, en donde la célula huésped es una célula CHO. Reivindicación 16: Un dispositivo de administración de boquilla que comprende el anticuerpo de cualquiera de las reivindicaciones 1 a 8 o la formulación farmacéutica de acuerdo con la reivindicación 13.The present invention relates to anti-VEGF-A/anti-IL6 antibodies, e.g., in the form of a bispecific Fab fragment, and methods of use thereof. Claim 1: An antibody that binds to human VEGF-A and human IL6 comprising a VH domain comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 18, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 19, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 20, and a VL domain comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17, comprising a heavy chain variable domain comprising an amino acid sequence of SEQ ID NO: 22 with up to 5 amino acid substitutions; and a light chain variable domain comprising an amino acid sequence of SEQ ID NO: 21 with up to 5 amino acid substitutions. Claim 9: An isolated nucleic acid encoding the antibody according to any one of claims 1 to 8. Claim 12: The method according to claim 11, wherein the host cell is a CHO cell. Claim 16: A nozzle delivery device comprising the antibody of any one of claims 1 to 8 or the pharmaceutical formulation according to claim 13.

ARP230101134A 2022-05-11 2023-05-09 ANTIBODY THAT BINDS TO VEGF-A AND IL6 AND METHODS OF USE AR129268A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP22172759 2022-05-11

Publications (1)

Publication Number Publication Date
AR129268A1 true AR129268A1 (en) 2024-08-07

Family

ID=81603574

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230101134A AR129268A1 (en) 2022-05-11 2023-05-09 ANTIBODY THAT BINDS TO VEGF-A AND IL6 AND METHODS OF USE

Country Status (16)

Country Link
US (1) US20250163139A1 (en)
EP (1) EP4522648A1 (en)
JP (1) JP7801491B2 (en)
KR (1) KR20250008903A (en)
CN (1) CN119173529A (en)
AR (1) AR129268A1 (en)
AU (1) AU2023267952A1 (en)
CA (1) CA3256863A1 (en)
CL (1) CL2024003373A1 (en)
CO (1) CO2024015714A2 (en)
CR (1) CR20240473A (en)
IL (1) IL316326A (en)
MX (1) MX2024013703A (en)
PE (1) PE20251283A1 (en)
TW (1) TW202402810A (en)
WO (1) WO2023217933A1 (en)

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
JP4124480B2 (en) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド Immunoglobulin variants
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ES2244066T3 (en) 1997-06-24 2005-12-01 Genentech, Inc. PROCEDURE AND COMPOSITIONS OF GALACTOSILATED GLICOPROTEINS.
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ATE375365T1 (en) 1998-04-02 2007-10-15 Genentech Inc ANTIBODIES VARIANTS AND FRAGMENTS THEREOF
PT1071700E (en) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
ID27960A (en) 1998-07-23 2001-05-03 Avebe B A COMPOSITION OF ADHESIVE
EP1141024B1 (en) 1999-01-15 2018-08-08 Genentech, Inc. POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CN102911987B (en) 2002-04-09 2015-09-30 协和发酵麒麟株式会社 The adorned cell of genome
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
CA2481656A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cells in which activity of the protein involved in transportation of gdp-fucose is reduced or lost
WO2003085119A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
DK2289936T3 (en) 2002-12-16 2017-07-31 Genentech Inc IMMUNGLOBULIN VARIATIONS AND APPLICATIONS THEREOF
NZ582315A (en) 2003-01-22 2011-01-28 Glycart Biotechnology Ag Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
PL1737891T3 (en) 2004-04-13 2013-08-30 Hoffmann La Roche Anti-p-selectin antibodies
TWI380996B (en) 2004-09-17 2013-01-01 Hoffmann La Roche Anti-ox40l antibodies
NZ553500A (en) 2004-09-23 2009-11-27 Genentech Inc Genentech Inc Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
RU2488597C2 (en) 2005-02-07 2013-07-27 Гликарт Биотехнологи Аг Antigen-binding molecules, which bind egfr, their coding vectors and their usage
CA2644405A1 (en) * 2006-03-13 2007-09-20 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
DE102007001370A1 (en) 2007-01-09 2008-07-10 Curevac Gmbh RNA-encoded antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
JP5577354B2 (en) 2009-01-29 2014-08-20 フォーサイト・ビジョン フォー・インコーポレーテッド Treatment device
US9000130B2 (en) 2010-06-08 2015-04-07 Genentech, Inc. Cysteine engineered antibodies and conjugates
HRP20211909T1 (en) 2010-08-05 2022-03-18 Forsight Vision4, Inc. Apparatus to treat an eye
CA2807508A1 (en) 2010-08-05 2012-02-09 Forsight Vision4, Inc. Subconjunctival implant for posterior segment drug delivery
KR101614195B1 (en) 2011-03-29 2016-04-20 로슈 글리카트 아게 Antibody fc variants
EP2726510B1 (en) * 2011-05-27 2023-03-08 F. Hoffmann-La Roche AG Dual targeting
ES3049671T3 (en) 2011-09-16 2025-12-17 Forsight Vision4 Inc Fluid exchange apparatus
WO2013116061A1 (en) 2012-02-03 2013-08-08 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
CN104125852B9 (en) 2012-02-15 2017-05-17 弗·哈夫曼-拉罗切有限公司 Fc-receptor based affinity chromatography
MX2015005831A (en) 2012-11-08 2015-09-24 Eleven Biotherapeutics Inc Il-6 antagonists and uses thereof.
HK1213578A1 (en) 2013-04-29 2016-07-08 豪夫迈‧罗氏有限公司 Human fcrn-binding modified antibodies and methods of use
WO2015085234A1 (en) 2013-12-06 2015-06-11 Forsight Vision4, Inc. Implantable therapeutic devices
UA117289C2 (en) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг MULTISPECIFIC ANTIBODY
JP6744292B2 (en) 2014-07-29 2020-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Multispecific antibody
MX2017003123A (en) 2014-09-12 2017-05-12 Genentech Inc Cysteine engineered antibodies and conjugates.
WO2021198034A1 (en) 2020-03-30 2021-10-07 F. Hoffmann-La Roche Ag Antibody that binds to vegf and pdgf-b and methods of use

Also Published As

Publication number Publication date
IL316326A (en) 2024-12-01
KR20250008903A (en) 2025-01-16
WO2023217933A1 (en) 2023-11-16
CN119173529A (en) 2024-12-20
EP4522648A1 (en) 2025-03-19
MX2024013703A (en) 2024-12-06
CR20240473A (en) 2025-01-06
CO2024015714A2 (en) 2025-04-16
CL2024003373A1 (en) 2025-03-14
PE20251283A1 (en) 2025-05-14
JP7801491B2 (en) 2026-01-16
AU2023267952A1 (en) 2024-10-31
CA3256863A1 (en) 2023-11-16
US20250163139A1 (en) 2025-05-22
JP2025521085A (en) 2025-07-08
TW202402810A (en) 2024-01-16

Similar Documents

Publication Publication Date Title
AR110659A1 (en) ANTI-NEUROPILIN ANTIGENS PROTEINS AND METHOD FOR USE
PE20230408A1 (en) ANTI-LILRB1 ANTIBODY AND USES THEREOF
PE20211863A1 (en) BISPECIFIC ANTIGEN BINDING MOLECULES INCLUDING CLONE 212 ANTI-FAP
PE20221511A1 (en) ANTI-LY6G6D ANTIBODIES AND METHODS OF USE
PE20211605A1 (en) ANTI-avß8 ANTIBODIES AND COMPOSITIONS AND USES OF THEM
PE20181952A1 (en) ANTI-LL-33 ANTIBODIES, COMPOSITIONS, METHODS AND USES OF THE SAME
AR065506A1 (en) OX40 ANTAGONIST ANTIBODIES AND ITS USE IN THE TREATMENT OF DISEASES
AR106991A1 (en) NEUTRALIZING ANTIBODIES OF THE HUMAN IMMUNODEFICIENCY VIRUS
AR040046A1 (en) ANTI-IGFR HUMAN NEUTRALIZING ANTIBODY
CN104903352A (en) Multivalent binding protein compositions
PE20210554A1 (en) ANTI-CXCR5 ANTIBODIES AND COMPOSITIONS AND USES THEREOF
PE20220763A1 (en) MATERIALS AND METHODS FOR MODULATING T-CELL-MEDIATED IMMUNITY
PE20231504A1 (en) SPECIFIC ANTIBODIES FOR KRAS AND THEIR USES
PE20181051A1 (en) ANTI-EPHA4 ANTIBODY
CO6311009A2 (en) ANTI-CD151 MONOCLONAL ANTIBODIES OF CHEMICAL AND HUMANIZED MURINE ORIGIN TO INHIBIT THE TUMOR GROWTH, SEQUENCES OF AMINO ACIDS AND NUCLEIC CODINGS, DERIVATIVE OR FUNCTIONAL FRAGMENTS AND PRODUCTS AND / OR COMPOSITIONS AND / OR COMPOSITIONS
PE20251639A1 (en) ANTIBODIES THAT BIND TO INTERLEUKIN 13 AND METHODS OF USE
AR123306A1 (en) FGFR3 ANTIBODIES AND METHODS OF USE
PE20230414A1 (en) TIE2 FIXING AGENTS AND METHODS OF USE
MX2024012479A (en) ANTI-TL1A ANTIBODIES AND METHODS OF USING THEM
AR129268A1 (en) ANTIBODY THAT BINDS TO VEGF-A AND IL6 AND METHODS OF USE
PE20250390A1 (en) Anti-C3 antibodies and antigen-binding fragments thereof and their uses for treating ophthalmic or ocular diseases
PE20231300A1 (en) ANTI-NOTCH2 ANTIBODIES AND METHODS OF USE
AR125074A1 (en) ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, ANTI-KLK5/KLK7 MULTI-SPECIFIC ANTIBODIES AND METHODS OF USE
PE20212269A1 (en) ANTI-TREM1 ANTIBODIES AND RELATED METHODS
AR124019A1 (en) POLYPEPTIDE CONSTRUCTIONS THAT BIND CD3